CorMedix Inc. 8-K

What Happened
CorMedix Inc. announced that on June 25, 2026 its Audit Committee approved the dismissal of CBIZ CPAs P.C. as the company’s independent registered public accounting firm and engaged Ernst & Young LLP (EY) as successor. CBIZ CPAs had been appointed on April 17, 2025 following the dismissal of Marcum LLP (after CBIZ acquired Marcum’s attest business). The report of CBIZ CPAs on the Company’s financial statements for the fiscal year ended December 31, 2025 was unmodified (no adverse opinion or disclaimer, and no qualifications). From April 17, 2025 through June 25, 2026 there were no disagreements with CBIZ CPAs, and no reportable events except a previously disclosed material weakness in internal control over financial reporting (reported in the Form 10‑K filed March 5, 2026). CBIZ CPAs has been authorized to respond fully to inquiries from EY about that reportable event.

Key Details

• Dismissal approved by Audit Committee: June 25, 2026.
• Successor auditor: Ernst & Young LLP (EY) engaged as successor independent registered public accounting firm.
• CBIZ CPAs’ report for year ended Dec 31, 2025: no adverse opinion, disclaimer, or qualifications.
• Only disclosed reportable event: material weakness in internal control (disclosed in the Form 10‑K filed March 5, 2026); CBIZ authorized to cooperate with EY.

Why It Matters
A change in independent auditor is a governance event investors should note because the new auditor will review the company’s financial controls and prior work. The filing confirms CBIZ’s 2025 audit opinion was unmodified and that there were no auditor disagreements, which reduces immediate concern about past reporting. However, the company previously disclosed a material weakness in its internal controls (timely review of significant, non‑routine transactions), and the successor auditor (EY) may review and assess remediation efforts. CorMedix has authorized the former auditor to cooperate with EY, which should help a smooth transition.